Table 1.
Demographic, clinical and genotypic characteristics of study cohorta
| Variable | Naïve: CD4<200 | Naïve: CD4>350 | Treated and failing | Total |
|---|---|---|---|---|
| Number | 28 | 34 | 60 | 122 |
| Age | 34 (22, 55) | 34 (19, 68) | 37 (20, 64) | 35 (19, 68) |
| Male | 12/28, 43% | 11/34, 32% | 24/60, 40% | 47/122, 39% |
| CD4 count | 99 (8, 195) | 507 (367, 1984) | 153 (8, 719) | 182 (8, 1984) |
| CD4% | 8 (1, 30) | 25.5 (10, 60) | 11 (1, 30) | 14 (1, 60) |
| Viral load (log10 copies/mL) | 5.1 (3.2, 6.3) | 4.3 (2.6, 5.3) | 4.4 (3.8, 6.0) | 4.6 (2.6, 6.3) |
| Antiretroviral regimen | ||||
| 3TC, D4T, NVP | 40/59, 68% | |||
| 3TC, AZT, NVP | 5/59, 8% | |||
| 3TC, D4T, EFV | 12/59, 20% | |||
| 3TC, AZT, EFV | 2/59, 3% | |||
| Years on antiretroviral therapy | 2.4 (0.92, 5.3) | |||
| Subtype | ||||
| A | 16/28, 57% | 21/30, 70% | 29/49, 59% | 66/107, 62% |
| D | 5/28, 18% | 3/30, 10% | 8/49, 16% | 16/107, 15% |
| AD | 2/28, 7% | 4/30, 13% | 6/49, 12% | 12/107, 11% |
| C | 4/28, 14% | 1/30, 3% | 1/49, 2% | 6/107, 6% |
| AC | 0/28, 0% | 1/30, 3% | 2/49, 4% | 3/107, 3% |
| Otherb | 1/28, 4% | 0/30, 0% | 3/49, 6% | 4/107, 4% |
a
Values are presented as median (range) for continuous variables and n/N, % for categorical variables;
b
AG (1/107, 1%); CD (1/107, 1%); undetermined (2/107, 2%). 3TC, lamivudine; D4T, stavudine; AZT, zidovudine; NVP, nevirapine; EFV, efavirenz.